nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—CYP2D6—Niacin—atherosclerosis	0.073	0.108	CbGbCtD
Fesoterodine—ABCB1—Ezetimibe—atherosclerosis	0.0659	0.0972	CbGbCtD
Fesoterodine—ABCB1—Simvastatin—atherosclerosis	0.0613	0.0903	CbGbCtD
Fesoterodine—ABCB1—Lovastatin—atherosclerosis	0.06	0.0884	CbGbCtD
Fesoterodine—ABCB1—Pravastatin—atherosclerosis	0.06	0.0884	CbGbCtD
Fesoterodine—CYP2D6—Simvastatin—atherosclerosis	0.0577	0.0851	CbGbCtD
Fesoterodine—CYP2D6—Pravastatin—atherosclerosis	0.0565	0.0833	CbGbCtD
Fesoterodine—CYP2D6—Lovastatin—atherosclerosis	0.0565	0.0833	CbGbCtD
Fesoterodine—CYP3A4—Rosuvastatin—atherosclerosis	0.0395	0.0582	CbGbCtD
Fesoterodine—CYP3A4—Ezetimibe—atherosclerosis	0.0395	0.0582	CbGbCtD
Fesoterodine—CYP3A4—Simvastatin—atherosclerosis	0.0367	0.0541	CbGbCtD
Fesoterodine—CYP3A4—Pravastatin—atherosclerosis	0.0359	0.053	CbGbCtD
Fesoterodine—CYP3A4—Lovastatin—atherosclerosis	0.0359	0.053	CbGbCtD
Fesoterodine—Musculoskeletal disorder—Rosuvastatin—atherosclerosis	0.00945	0.0451	CcSEcCtD
Fesoterodine—Musculoskeletal disorder—Simvastatin—atherosclerosis	0.00749	0.0358	CcSEcCtD
Fesoterodine—Hepatic enzyme increased—Rosuvastatin—atherosclerosis	0.00357	0.017	CcSEcCtD
Fesoterodine—Gamma-glutamyltransferase increased—Ezetimibe—atherosclerosis	0.00341	0.0163	CcSEcCtD
Fesoterodine—Gastrooesophageal reflux disease—Ezetimibe—atherosclerosis	0.00311	0.0148	CcSEcCtD
Fesoterodine—Gamma-glutamyltransferase increased—Pravastatin—atherosclerosis	0.00294	0.014	CcSEcCtD
Fesoterodine—Gastroenteritis—Rosuvastatin—atherosclerosis	0.00276	0.0132	CcSEcCtD
Fesoterodine—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00184	0.00876	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.0018	0.00857	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00179	0.00852	CcSEcCtD
Fesoterodine—Face oedema—Niacin—atherosclerosis	0.00172	0.00822	CcSEcCtD
Fesoterodine—Abdominal discomfort—Lovastatin—atherosclerosis	0.00172	0.00821	CcSEcCtD
Fesoterodine—Urinary retention—Niacin—atherosclerosis	0.0017	0.00809	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.00164	0.00781	CcSEcCtD
Fesoterodine—Dry skin—Niacin—atherosclerosis	0.00163	0.0078	CcSEcCtD
Fesoterodine—Dry skin—Pravastatin—atherosclerosis	0.00161	0.00768	CcSEcCtD
Fesoterodine—Abdominal discomfort—Simvastatin—atherosclerosis	0.00161	0.00768	CcSEcCtD
Fesoterodine—Infestation NOS—Ezetimibe—atherosclerosis	0.00157	0.00749	CcSEcCtD
Fesoterodine—Infestation—Ezetimibe—atherosclerosis	0.00157	0.00749	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00156	0.00745	CcSEcCtD
Fesoterodine—Urinary tract infection—Lovastatin—atherosclerosis	0.00156	0.00742	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00155	0.00739	CcSEcCtD
Fesoterodine—Angina pectoris—Niacin—atherosclerosis	0.0015	0.00717	CcSEcCtD
Fesoterodine—Mental disorder—Rosuvastatin—atherosclerosis	0.00148	0.00709	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00148	0.00708	CcSEcCtD
Fesoterodine—Angina pectoris—Pravastatin—atherosclerosis	0.00148	0.00706	CcSEcCtD
Fesoterodine—Flatulence—Rosuvastatin—atherosclerosis	0.00145	0.00694	CcSEcCtD
Fesoterodine—Dysuria—Pravastatin—atherosclerosis	0.00142	0.00677	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00141	0.00673	CcSEcCtD
Fesoterodine—Oedema peripheral—Ezetimibe—atherosclerosis	0.00139	0.00662	CcSEcCtD
Fesoterodine—Angioedema—Rosuvastatin—atherosclerosis	0.00135	0.00644	CcSEcCtD
Fesoterodine—Urinary tract infection—Pravastatin—atherosclerosis	0.00132	0.00628	CcSEcCtD
Fesoterodine—Cough—Rosuvastatin—atherosclerosis	0.00129	0.00615	CcSEcCtD
Fesoterodine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00127	0.00606	CcSEcCtD
Fesoterodine—Mental disorder—Ezetimibe—atherosclerosis	0.00123	0.00589	CcSEcCtD
Fesoterodine—Flatulence—Lovastatin—atherosclerosis	0.00123	0.00588	CcSEcCtD
Fesoterodine—Dysgeusia—Lovastatin—atherosclerosis	0.00122	0.00584	CcSEcCtD
Fesoterodine—Oedema peripheral—Niacin—atherosclerosis	0.00122	0.0058	CcSEcCtD
Fesoterodine—Confusional state—Rosuvastatin—atherosclerosis	0.00121	0.0058	CcSEcCtD
Fesoterodine—Back pain—Lovastatin—atherosclerosis	0.00121	0.00577	CcSEcCtD
Fesoterodine—Flatulence—Ezetimibe—atherosclerosis	0.00121	0.00577	CcSEcCtD
Fesoterodine—Infection—Rosuvastatin—atherosclerosis	0.0012	0.00571	CcSEcCtD
Fesoterodine—Back pain—Ezetimibe—atherosclerosis	0.00119	0.00566	CcSEcCtD
Fesoterodine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00118	0.00564	CcSEcCtD
Fesoterodine—Vision blurred—Lovastatin—atherosclerosis	0.00118	0.00562	CcSEcCtD
Fesoterodine—Mental disorder—Simvastatin—atherosclerosis	0.00118	0.00562	CcSEcCtD
Fesoterodine—Eye disorder—Niacin—atherosclerosis	0.00115	0.0055	CcSEcCtD
Fesoterodine—Flatulence—Simvastatin—atherosclerosis	0.00115	0.0055	CcSEcCtD
Fesoterodine—Dysgeusia—Simvastatin—atherosclerosis	0.00115	0.00547	CcSEcCtD
Fesoterodine—Angioedema—Lovastatin—atherosclerosis	0.00114	0.00545	CcSEcCtD
Fesoterodine—Cardiac disorder—Pravastatin—atherosclerosis	0.00113	0.00538	CcSEcCtD
Fesoterodine—Vertigo—Lovastatin—atherosclerosis	0.00112	0.00536	CcSEcCtD
Fesoterodine—Angioedema—Ezetimibe—atherosclerosis	0.00112	0.00535	CcSEcCtD
Fesoterodine—Vision blurred—Simvastatin—atherosclerosis	0.0011	0.00526	CcSEcCtD
Fesoterodine—Insomnia—Rosuvastatin—atherosclerosis	0.00109	0.0052	CcSEcCtD
Fesoterodine—Palpitations—Ezetimibe—atherosclerosis	0.00108	0.00517	CcSEcCtD
Fesoterodine—Cough—Ezetimibe—atherosclerosis	0.00107	0.00511	CcSEcCtD
Fesoterodine—Angioedema—Simvastatin—atherosclerosis	0.00107	0.0051	CcSEcCtD
Fesoterodine—Chest pain—Lovastatin—atherosclerosis	0.00106	0.00508	CcSEcCtD
Fesoterodine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00106	0.00506	CcSEcCtD
Fesoterodine—Flatulence—Niacin—atherosclerosis	0.00106	0.00505	CcSEcCtD
Fesoterodine—Vertigo—Simvastatin—atherosclerosis	0.00105	0.00502	CcSEcCtD
Fesoterodine—Chest pain—Ezetimibe—atherosclerosis	0.00104	0.00498	CcSEcCtD
Fesoterodine—Flatulence—Pravastatin—atherosclerosis	0.00104	0.00497	CcSEcCtD
Fesoterodine—Dry mouth—Lovastatin—atherosclerosis	0.00104	0.00497	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00104	0.00495	CcSEcCtD
Fesoterodine—Dysgeusia—Pravastatin—atherosclerosis	0.00104	0.00494	CcSEcCtD
Fesoterodine—Constipation—Rosuvastatin—atherosclerosis	0.00103	0.00492	CcSEcCtD
Fesoterodine—Confusional state—Lovastatin—atherosclerosis	0.00103	0.00491	CcSEcCtD
Fesoterodine—Dry mouth—Ezetimibe—atherosclerosis	0.00102	0.00487	CcSEcCtD
Fesoterodine—Infection—Lovastatin—atherosclerosis	0.00101	0.00484	CcSEcCtD
Fesoterodine—Vision blurred—Niacin—atherosclerosis	0.00101	0.00483	CcSEcCtD
Fesoterodine—Confusional state—Ezetimibe—atherosclerosis	0.00101	0.00482	CcSEcCtD
Fesoterodine—Vision blurred—Pravastatin—atherosclerosis	0.000997	0.00476	CcSEcCtD
Fesoterodine—Chest pain—Simvastatin—atherosclerosis	0.000996	0.00475	CcSEcCtD
Fesoterodine—Infection—Ezetimibe—atherosclerosis	0.000994	0.00475	CcSEcCtD
Fesoterodine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000992	0.00474	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000985	0.0047	CcSEcCtD
Fesoterodine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000982	0.00469	CcSEcCtD
Fesoterodine—Angioedema—Niacin—atherosclerosis	0.000981	0.00468	CcSEcCtD
Fesoterodine—Skin disorder—Ezetimibe—atherosclerosis	0.000972	0.00464	CcSEcCtD
Fesoterodine—Angioedema—Pravastatin—atherosclerosis	0.000966	0.00461	CcSEcCtD
Fesoterodine—Vertigo—Niacin—atherosclerosis	0.000965	0.00461	CcSEcCtD
Fesoterodine—Confusional state—Simvastatin—atherosclerosis	0.000962	0.00459	CcSEcCtD
Fesoterodine—Urticaria—Rosuvastatin—atherosclerosis	0.000957	0.00457	CcSEcCtD
Fesoterodine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000952	0.00454	CcSEcCtD
Fesoterodine—Vertigo—Pravastatin—atherosclerosis	0.00095	0.00453	CcSEcCtD
Fesoterodine—Palpitations—Niacin—atherosclerosis	0.000949	0.00453	CcSEcCtD
Fesoterodine—Infection—Simvastatin—atherosclerosis	0.000948	0.00453	CcSEcCtD
Fesoterodine—Cough—Niacin—atherosclerosis	0.000937	0.00447	CcSEcCtD
Fesoterodine—Insomnia—Lovastatin—atherosclerosis	0.000923	0.00441	CcSEcCtD
Fesoterodine—Cough—Pravastatin—atherosclerosis	0.000923	0.0044	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000908	0.00433	CcSEcCtD
Fesoterodine—Insomnia—Ezetimibe—atherosclerosis	0.000905	0.00432	CcSEcCtD
Fesoterodine—Chest pain—Pravastatin—atherosclerosis	0.0009	0.0043	CcSEcCtD
Fesoterodine—Dyspepsia—Lovastatin—atherosclerosis	0.000898	0.00429	CcSEcCtD
Fesoterodine—Dry mouth—Niacin—atherosclerosis	0.000894	0.00427	CcSEcCtD
Fesoterodine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000887	0.00423	CcSEcCtD
Fesoterodine—Dyspepsia—Ezetimibe—atherosclerosis	0.000881	0.00421	CcSEcCtD
Fesoterodine—Fatigue—Lovastatin—atherosclerosis	0.00088	0.0042	CcSEcCtD
Fesoterodine—Constipation—Lovastatin—atherosclerosis	0.000873	0.00417	CcSEcCtD
Fesoterodine—Confusional state—Pravastatin—atherosclerosis	0.00087	0.00415	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000864	0.00412	CcSEcCtD
Fesoterodine—Asthenia—Rosuvastatin—atherosclerosis	0.000864	0.00412	CcSEcCtD
Fesoterodine—Insomnia—Simvastatin—atherosclerosis	0.000863	0.00412	CcSEcCtD
Fesoterodine—Fatigue—Ezetimibe—atherosclerosis	0.000863	0.00412	CcSEcCtD
Fesoterodine—Infection—Pravastatin—atherosclerosis	0.000857	0.00409	CcSEcCtD
Fesoterodine—Constipation—Ezetimibe—atherosclerosis	0.000856	0.00409	CcSEcCtD
Fesoterodine—Tachycardia—Niacin—atherosclerosis	0.000855	0.00408	CcSEcCtD
Fesoterodine—Pruritus—Rosuvastatin—atherosclerosis	0.000852	0.00407	CcSEcCtD
Fesoterodine—Skin disorder—Niacin—atherosclerosis	0.000851	0.00406	CcSEcCtD
Fesoterodine—Feeling abnormal—Lovastatin—atherosclerosis	0.000841	0.00401	CcSEcCtD
Fesoterodine—Dyspepsia—Simvastatin—atherosclerosis	0.00084	0.00401	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000834	0.00398	CcSEcCtD
Fesoterodine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000825	0.00394	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000824	0.00393	CcSEcCtD
Fesoterodine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000824	0.00393	CcSEcCtD
Fesoterodine—Fatigue—Simvastatin—atherosclerosis	0.000823	0.00393	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000818	0.00391	CcSEcCtD
Fesoterodine—Constipation—Simvastatin—atherosclerosis	0.000816	0.0039	CcSEcCtD
Fesoterodine—Urticaria—Lovastatin—atherosclerosis	0.000811	0.00387	CcSEcCtD
Fesoterodine—Abdominal pain—Lovastatin—atherosclerosis	0.000807	0.00385	CcSEcCtD
Fesoterodine—Dizziness—Rosuvastatin—atherosclerosis	0.000796	0.0038	CcSEcCtD
Fesoterodine—Urticaria—Ezetimibe—atherosclerosis	0.000795	0.0038	CcSEcCtD
Fesoterodine—Insomnia—Niacin—atherosclerosis	0.000793	0.00378	CcSEcCtD
Fesoterodine—Abdominal pain—Ezetimibe—atherosclerosis	0.000791	0.00378	CcSEcCtD
Fesoterodine—Feeling abnormal—Simvastatin—atherosclerosis	0.000787	0.00375	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000781	0.00373	CcSEcCtD
Fesoterodine—Insomnia—Pravastatin—atherosclerosis	0.000781	0.00373	CcSEcCtD
Fesoterodine—Somnolence—Niacin—atherosclerosis	0.000779	0.00372	CcSEcCtD
Fesoterodine—Dyspepsia—Niacin—atherosclerosis	0.000772	0.00368	CcSEcCtD
Fesoterodine—Dyspepsia—Pravastatin—atherosclerosis	0.00076	0.00363	CcSEcCtD
Fesoterodine—Rash—Rosuvastatin—atherosclerosis	0.000759	0.00362	CcSEcCtD
Fesoterodine—Dermatitis—Rosuvastatin—atherosclerosis	0.000759	0.00362	CcSEcCtD
Fesoterodine—Urticaria—Simvastatin—atherosclerosis	0.000758	0.00362	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000757	0.00361	CcSEcCtD
Fesoterodine—Abdominal pain—Simvastatin—atherosclerosis	0.000755	0.0036	CcSEcCtD
Fesoterodine—Headache—Rosuvastatin—atherosclerosis	0.000754	0.0036	CcSEcCtD
Fesoterodine—Hypersensitivity—Lovastatin—atherosclerosis	0.000752	0.00359	CcSEcCtD
Fesoterodine—Fatigue—Pravastatin—atherosclerosis	0.000744	0.00355	CcSEcCtD
Fesoterodine—Constipation—Pravastatin—atherosclerosis	0.000738	0.00352	CcSEcCtD
Fesoterodine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000737	0.00352	CcSEcCtD
Fesoterodine—Asthenia—Lovastatin—atherosclerosis	0.000732	0.00349	CcSEcCtD
Fesoterodine—Pruritus—Lovastatin—atherosclerosis	0.000722	0.00345	CcSEcCtD
Fesoterodine—Asthenia—Ezetimibe—atherosclerosis	0.000718	0.00343	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Niacin—atherosclerosis	0.000717	0.00342	CcSEcCtD
Fesoterodine—Nausea—Rosuvastatin—atherosclerosis	0.000715	0.00341	CcSEcCtD
Fesoterodine—Feeling abnormal—Pravastatin—atherosclerosis	0.000711	0.00339	CcSEcCtD
Fesoterodine—Pruritus—Ezetimibe—atherosclerosis	0.000708	0.00338	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000706	0.00337	CcSEcCtD
Fesoterodine—Hypersensitivity—Simvastatin—atherosclerosis	0.000703	0.00336	CcSEcCtD
Fesoterodine—Diarrhoea—Lovastatin—atherosclerosis	0.000698	0.00333	CcSEcCtD
Fesoterodine—Urticaria—Niacin—atherosclerosis	0.000696	0.00332	CcSEcCtD
Fesoterodine—Abdominal pain—Niacin—atherosclerosis	0.000693	0.00331	CcSEcCtD
Fesoterodine—Urticaria—Pravastatin—atherosclerosis	0.000686	0.00327	CcSEcCtD
Fesoterodine—Asthenia—Simvastatin—atherosclerosis	0.000685	0.00327	CcSEcCtD
Fesoterodine—Diarrhoea—Ezetimibe—atherosclerosis	0.000685	0.00327	CcSEcCtD
Fesoterodine—Abdominal pain—Pravastatin—atherosclerosis	0.000682	0.00326	CcSEcCtD
Fesoterodine—Pruritus—Simvastatin—atherosclerosis	0.000675	0.00322	CcSEcCtD
Fesoterodine—Dizziness—Lovastatin—atherosclerosis	0.000675	0.00322	CcSEcCtD
Fesoterodine—Dizziness—Ezetimibe—atherosclerosis	0.000662	0.00316	CcSEcCtD
Fesoterodine—Diarrhoea—Simvastatin—atherosclerosis	0.000653	0.00312	CcSEcCtD
Fesoterodine—Hypersensitivity—Niacin—atherosclerosis	0.000646	0.00308	CcSEcCtD
Fesoterodine—Rash—Lovastatin—atherosclerosis	0.000643	0.00307	CcSEcCtD
Fesoterodine—Dermatitis—Lovastatin—atherosclerosis	0.000643	0.00307	CcSEcCtD
Fesoterodine—Headache—Lovastatin—atherosclerosis	0.000639	0.00305	CcSEcCtD
Fesoterodine—Hypersensitivity—Pravastatin—atherosclerosis	0.000636	0.00303	CcSEcCtD
Fesoterodine—Dizziness—Simvastatin—atherosclerosis	0.000631	0.00301	CcSEcCtD
Fesoterodine—Rash—Ezetimibe—atherosclerosis	0.000631	0.00301	CcSEcCtD
Fesoterodine—Dermatitis—Ezetimibe—atherosclerosis	0.000631	0.00301	CcSEcCtD
Fesoterodine—Asthenia—Niacin—atherosclerosis	0.000629	0.003	CcSEcCtD
Fesoterodine—Headache—Ezetimibe—atherosclerosis	0.000627	0.00299	CcSEcCtD
Fesoterodine—Pruritus—Niacin—atherosclerosis	0.00062	0.00296	CcSEcCtD
Fesoterodine—Asthenia—Pravastatin—atherosclerosis	0.000619	0.00296	CcSEcCtD
Fesoterodine—Pruritus—Pravastatin—atherosclerosis	0.000611	0.00291	CcSEcCtD
Fesoterodine—Nausea—Lovastatin—atherosclerosis	0.000606	0.00289	CcSEcCtD
Fesoterodine—Rash—Simvastatin—atherosclerosis	0.000602	0.00287	CcSEcCtD
Fesoterodine—Dermatitis—Simvastatin—atherosclerosis	0.000601	0.00287	CcSEcCtD
Fesoterodine—Diarrhoea—Niacin—atherosclerosis	0.0006	0.00286	CcSEcCtD
Fesoterodine—Headache—Simvastatin—atherosclerosis	0.000598	0.00285	CcSEcCtD
Fesoterodine—Nausea—Ezetimibe—atherosclerosis	0.000595	0.00284	CcSEcCtD
Fesoterodine—Diarrhoea—Pravastatin—atherosclerosis	0.00059	0.00282	CcSEcCtD
Fesoterodine—Dizziness—Niacin—atherosclerosis	0.00058	0.00277	CcSEcCtD
Fesoterodine—Dizziness—Pravastatin—atherosclerosis	0.000571	0.00272	CcSEcCtD
Fesoterodine—Nausea—Simvastatin—atherosclerosis	0.000567	0.00271	CcSEcCtD
Fesoterodine—Rash—Niacin—atherosclerosis	0.000553	0.00264	CcSEcCtD
Fesoterodine—Dermatitis—Niacin—atherosclerosis	0.000552	0.00264	CcSEcCtD
Fesoterodine—Headache—Niacin—atherosclerosis	0.000549	0.00262	CcSEcCtD
Fesoterodine—Rash—Pravastatin—atherosclerosis	0.000544	0.0026	CcSEcCtD
Fesoterodine—Dermatitis—Pravastatin—atherosclerosis	0.000544	0.00259	CcSEcCtD
Fesoterodine—Headache—Pravastatin—atherosclerosis	0.000541	0.00258	CcSEcCtD
Fesoterodine—Nausea—Niacin—atherosclerosis	0.000521	0.00248	CcSEcCtD
Fesoterodine—Nausea—Pravastatin—atherosclerosis	0.000513	0.00245	CcSEcCtD
Fesoterodine—CHRM3—Signaling Pathways—SOCS3—atherosclerosis	1.89e-05	0.000169	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SOCS3—atherosclerosis	1.88e-05	0.000167	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP3—atherosclerosis	1.84e-05	0.000164	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—HMGCR—atherosclerosis	1.83e-05	0.000163	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP3—atherosclerosis	1.83e-05	0.000163	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—SCARB1—atherosclerosis	1.83e-05	0.000163	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IGF2—atherosclerosis	1.83e-05	0.000163	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IGF2—atherosclerosis	1.82e-05	0.000162	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—MAPK3—atherosclerosis	1.82e-05	0.000162	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CG—atherosclerosis	1.82e-05	0.000162	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—MTHFR—atherosclerosis	1.82e-05	0.000162	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP3—atherosclerosis	1.81e-05	0.000161	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IGF2—atherosclerosis	1.8e-05	0.000161	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.8e-05	0.00016	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—INS—atherosclerosis	1.8e-05	0.00016	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	1.8e-05	0.00016	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PPARA—atherosclerosis	1.78e-05	0.000159	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—APOB—atherosclerosis	1.77e-05	0.000158	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCL2—atherosclerosis	1.77e-05	0.000158	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—APOB—atherosclerosis	1.77e-05	0.000158	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CXCL8—atherosclerosis	1.76e-05	0.000157	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CXCL8—atherosclerosis	1.75e-05	0.000156	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—APOB—atherosclerosis	1.75e-05	0.000156	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EDN1—atherosclerosis	1.75e-05	0.000156	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—MAPK3—atherosclerosis	1.74e-05	0.000155	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EDN1—atherosclerosis	1.74e-05	0.000155	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IGF1—atherosclerosis	1.74e-05	0.000155	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CXCL8—atherosclerosis	1.74e-05	0.000155	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCL5—atherosclerosis	1.73e-05	0.000154	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AGT—atherosclerosis	1.73e-05	0.000154	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCL5—atherosclerosis	1.73e-05	0.000154	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—HMGCR—atherosclerosis	1.73e-05	0.000154	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EDN1—atherosclerosis	1.72e-05	0.000154	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—INS—atherosclerosis	1.72e-05	0.000154	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCL5—atherosclerosis	1.71e-05	0.000152	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.71e-05	0.000152	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.71e-05	0.000152	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—APOA2—atherosclerosis	1.71e-05	0.000152	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.71e-05	0.000152	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCL2—atherosclerosis	1.69e-05	0.000151	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—LPL—atherosclerosis	1.69e-05	0.000151	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—APOE—atherosclerosis	1.69e-05	0.000151	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—LPL—atherosclerosis	1.69e-05	0.00015	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.69e-05	0.00015	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—CAV1—atherosclerosis	1.68e-05	0.000149	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—APOA1—atherosclerosis	1.67e-05	0.000149	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—LPL—atherosclerosis	1.67e-05	0.000149	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IGF1—atherosclerosis	1.67e-05	0.000149	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SERPINE1—atherosclerosis	1.65e-05	0.000147	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PRKCG—atherosclerosis	1.65e-05	0.000147	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PRKCG—atherosclerosis	1.64e-05	0.000146	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ABCA1—atherosclerosis	1.63e-05	0.000146	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—LPA—atherosclerosis	1.63e-05	0.000145	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PRKCG—atherosclerosis	1.63e-05	0.000145	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SPP1—atherosclerosis	1.6e-05	0.000143	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SPP1—atherosclerosis	1.6e-05	0.000143	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CXCL8—atherosclerosis	1.6e-05	0.000142	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CXCL8—atherosclerosis	1.59e-05	0.000142	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SPP1—atherosclerosis	1.58e-05	0.000141	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SERPINE1—atherosclerosis	1.58e-05	0.000141	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—NOS3—atherosclerosis	1.58e-05	0.000141	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—BGN—atherosclerosis	1.58e-05	0.000141	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CXCL8—atherosclerosis	1.58e-05	0.000141	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—APOA5—atherosclerosis	1.56e-05	0.000139	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.54e-05	0.000137	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CG—atherosclerosis	1.53e-05	0.000136	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—NOS3—atherosclerosis	1.51e-05	0.000135	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.5e-05	0.000134	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PDGFB—atherosclerosis	1.48e-05	0.000132	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PDGFB—atherosclerosis	1.48e-05	0.000132	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PPARG—atherosclerosis	1.47e-05	0.000131	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PDGFB—atherosclerosis	1.47e-05	0.000131	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.45e-05	0.000129	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AGT—atherosclerosis	1.45e-05	0.000129	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—INS—atherosclerosis	1.45e-05	0.000129	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AGT—atherosclerosis	1.44e-05	0.000129	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AGT—atherosclerosis	1.43e-05	0.000128	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—LEP—atherosclerosis	1.42e-05	0.000127	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—APOE—atherosclerosis	1.42e-05	0.000127	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—LEP—atherosclerosis	1.42e-05	0.000126	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—APOE—atherosclerosis	1.42e-05	0.000126	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CAV1—atherosclerosis	1.41e-05	0.000125	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—APOA1—atherosclerosis	1.4e-05	0.000125	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CAV1—atherosclerosis	1.4e-05	0.000125	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—APOE—atherosclerosis	1.4e-05	0.000125	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—LEP—atherosclerosis	1.4e-05	0.000125	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—HMOX1—atherosclerosis	1.4e-05	0.000125	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CXCL8—atherosclerosis	1.4e-05	0.000125	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—APOA1—atherosclerosis	1.4e-05	0.000125	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CAV1—atherosclerosis	1.39e-05	0.000124	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—APOA1—atherosclerosis	1.39e-05	0.000123	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ESR1—atherosclerosis	1.36e-05	0.000121	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—AKT1—atherosclerosis	1.35e-05	0.00012	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ESR1—atherosclerosis	1.35e-05	0.00012	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—APOB—atherosclerosis	1.34e-05	0.00012	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CXCL8—atherosclerosis	1.34e-05	0.000119	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—F2—atherosclerosis	1.34e-05	0.000119	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ESR1—atherosclerosis	1.34e-05	0.000119	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—F2—atherosclerosis	1.33e-05	0.000119	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—IL6—atherosclerosis	1.33e-05	0.000119	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—ALB—atherosclerosis	1.33e-05	0.000118	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—F2—atherosclerosis	1.32e-05	0.000118	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.32e-05	0.000118	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GSTM1—atherosclerosis	1.31e-05	0.000116	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.3e-05	0.000116	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—AKT1—atherosclerosis	1.29e-05	0.000115	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—LIPC—atherosclerosis	1.29e-05	0.000115	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—APOC3—atherosclerosis	1.29e-05	0.000115	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	1.28e-05	0.000114	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—LPL—atherosclerosis	1.28e-05	0.000114	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—LDLR—atherosclerosis	1.28e-05	0.000114	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CG—atherosclerosis	1.28e-05	0.000114	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL6—atherosclerosis	1.27e-05	0.000114	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—NOS3—atherosclerosis	1.27e-05	0.000113	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MMP9—atherosclerosis	1.27e-05	0.000113	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CG—atherosclerosis	1.26e-05	0.000113	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—APOB—atherosclerosis	1.26e-05	0.000113	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—NFKB1—atherosclerosis	1.25e-05	0.000112	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GPX1—atherosclerosis	1.25e-05	0.000111	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CETP—atherosclerosis	1.25e-05	0.000111	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK8—atherosclerosis	1.23e-05	0.00011	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.23e-05	0.00011	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—AKT1—atherosclerosis	1.23e-05	0.000109	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	1.23e-05	0.000109	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—MAPK3—atherosclerosis	1.22e-05	0.000109	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CD36—atherosclerosis	1.22e-05	0.000109	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—INS—atherosclerosis	1.21e-05	0.000108	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MMP9—atherosclerosis	1.21e-05	0.000108	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—MAPK3—atherosclerosis	1.21e-05	0.000108	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—INS—atherosclerosis	1.21e-05	0.000108	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—LPL—atherosclerosis	1.21e-05	0.000108	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—NFKB1—atherosclerosis	1.2e-05	0.000107	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—INS—atherosclerosis	1.2e-05	0.000107	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.2e-05	0.000107	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCL2—atherosclerosis	1.19e-05	0.000106	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCL2—atherosclerosis	1.19e-05	0.000106	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK8—atherosclerosis	1.18e-05	0.000105	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCL2—atherosclerosis	1.18e-05	0.000105	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GPX1—atherosclerosis	1.18e-05	0.000105	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—AKT1—atherosclerosis	1.18e-05	0.000105	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IGF1—atherosclerosis	1.17e-05	0.000105	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IGF1—atherosclerosis	1.17e-05	0.000104	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTGS2—atherosclerosis	1.16e-05	0.000103	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IGF1—atherosclerosis	1.16e-05	0.000103	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—MTHFR—atherosclerosis	1.15e-05	0.000103	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CD36—atherosclerosis	1.15e-05	0.000102	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—VEGFA—atherosclerosis	1.14e-05	0.000101	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PPARA—atherosclerosis	1.13e-05	0.000101	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.13e-05	0.000101	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—STAT3—atherosclerosis	1.13e-05	0.0001	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	1.11e-05	9.93e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	1.11e-05	9.9e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	1.1e-05	9.8e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AGT—atherosclerosis	1.1e-05	9.77e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—VEGFA—atherosclerosis	1.09e-05	9.7e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.09e-05	9.69e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—STAT3—atherosclerosis	1.08e-05	9.61e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK3—atherosclerosis	1.08e-05	9.58e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—APOE—atherosclerosis	1.07e-05	9.57e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PPARA—atherosclerosis	1.07e-05	9.51e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CAV1—atherosclerosis	1.06e-05	9.48e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NOS3—atherosclerosis	1.06e-05	9.48e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—APOA1—atherosclerosis	1.06e-05	9.46e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NOS3—atherosclerosis	1.06e-05	9.45e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NOS3—atherosclerosis	1.05e-05	9.36e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TGFB1—atherosclerosis	1.04e-05	9.3e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AGT—atherosclerosis	1.03e-05	9.21e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK3—atherosclerosis	1.03e-05	9.18e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—APOE—atherosclerosis	1.01e-05	9.02e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.01e-05	8.97e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CAV1—atherosclerosis	1e-05	8.94e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—APOA1—atherosclerosis	1e-05	8.92e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	9.99e-06	8.9e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CG—atherosclerosis	9.69e-06	8.64e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	9.43e-06	8.41e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	9.4e-06	8.38e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PPARG—atherosclerosis	9.35e-06	8.34e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	9.31e-06	8.3e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—INS—atherosclerosis	9.17e-06	8.18e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	9.13e-06	8.14e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	9.11e-06	8.12e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	9.09e-06	8.1e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	9e-06	8.02e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL6—atherosclerosis	8.97e-06	8e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL6—atherosclerosis	8.94e-06	7.97e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL6—atherosclerosis	8.86e-06	7.89e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PPARG—atherosclerosis	8.81e-06	7.86e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—INS—atherosclerosis	8.65e-06	7.71e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HMOX1—atherosclerosis	8.63e-06	7.69e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP9—atherosclerosis	8.53e-06	7.61e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP9—atherosclerosis	8.51e-06	7.58e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	8.44e-06	7.53e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP9—atherosclerosis	8.42e-06	7.51e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	8.42e-06	7.5e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ALB—atherosclerosis	8.41e-06	7.5e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	8.33e-06	7.43e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	8.3e-06	7.4e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	8.28e-06	7.38e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	8.27e-06	7.37e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—APOB—atherosclerosis	8.27e-06	7.37e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	8.25e-06	7.35e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	8.19e-06	7.3e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	8.17e-06	7.28e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NOS3—atherosclerosis	8.05e-06	7.17e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTM1—atherosclerosis	8.04e-06	7.17e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ALB—atherosclerosis	7.93e-06	7.07e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—LPL—atherosclerosis	7.89e-06	7.04e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL6—atherosclerosis	7.86e-06	7.01e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GPX1—atherosclerosis	7.7e-06	6.86e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	7.66e-06	6.83e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	7.64e-06	6.81e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—STAT3—atherosclerosis	7.59e-06	6.76e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NOS3—atherosclerosis	7.58e-06	6.76e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	7.56e-06	6.74e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—STAT3—atherosclerosis	7.56e-06	6.74e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL6—atherosclerosis	7.53e-06	6.71e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CD36—atherosclerosis	7.5e-06	6.69e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—STAT3—atherosclerosis	7.49e-06	6.68e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTGS2—atherosclerosis	7.36e-06	6.56e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—AKT1—atherosclerosis	7.25e-06	6.46e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	7.25e-06	6.46e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	7.23e-06	6.44e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	7.16e-06	6.38e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—MTHFR—atherosclerosis	7.11e-06	6.34e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	7.03e-06	6.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	7.01e-06	6.25e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PPARA—atherosclerosis	6.97e-06	6.22e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—AKT1—atherosclerosis	6.94e-06	6.19e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	6.94e-06	6.19e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTGS2—atherosclerosis	6.93e-06	6.18e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AGT—atherosclerosis	6.75e-06	6.02e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—APOE—atherosclerosis	6.62e-06	5.9e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CAV1—atherosclerosis	6.56e-06	5.84e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—APOA1—atherosclerosis	6.54e-06	5.83e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	5.97e-06	5.32e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AKT1—atherosclerosis	5.83e-06	5.2e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PPARG—atherosclerosis	5.76e-06	5.14e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—INS—atherosclerosis	5.65e-06	5.04e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6—atherosclerosis	5.3e-06	4.72e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6—atherosclerosis	5.28e-06	4.71e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6—atherosclerosis	5.23e-06	4.66e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALB—atherosclerosis	5.18e-06	4.62e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NOS3—atherosclerosis	4.96e-06	4.42e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AKT1—atherosclerosis	4.89e-06	4.36e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AKT1—atherosclerosis	4.87e-06	4.34e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AKT1—atherosclerosis	4.83e-06	4.3e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTGS2—atherosclerosis	4.53e-06	4.04e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AKT1—atherosclerosis	3.7e-06	3.3e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AKT1—atherosclerosis	3.49e-06	3.11e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AKT1—atherosclerosis	2.28e-06	2.03e-05	CbGpPWpGaD
